Tourmaline Bio, Inc. — Director's Dealing 2021

May 7, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Talaris Therapeutics, Inc. (TALS)
CIK: 0001827506
Period of Report: 2021-05-06

Reporting Person: Krieger Nancy (Chief Medical Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	250233	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$5.72	2030-10-02	Common Stock (109485)		Direct
Stock Option (Right to Buy)	$3.90	2030-08-20	Common Stock (33043)		Direct

Footnotes

F1: The shares underlying this option shall vest in 48 equal monthly installments following October 2, 2020, subject to the reporting person's continuous service.

F2: The shares underlying this option shall vest in 48 equal monthly installments following August 20, 2020, subject to the reporting person's continuous service.